AFM-13 is a monoclonal antibody commercialized by Affimed, with a leading Phase II program in Peripheral T-Cell Lymphomas (PTCL). According to Globaldata, it is involved in 6 clinical trials, of which 5 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of AFM-13’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for AFM-13 is expected to reach an annual total of $137 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

AFM-13 Overview

AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A.

Affimed Overview

Affimed, is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. It develops pipeline products for the treatment of cancers. The company develops products from the proprietary fit-for-purpose ROCK platform. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany.

The company reported revenues of (Euro) EUR40.4 million for the fiscal year ended December 2021 (FY2021), an increase of 42.3% over FY2020. The operating loss of the company was EUR64 million in FY2021, compared to an operating loss of EUR34.7 million in FY2020. The net loss of the company was EUR57.5 million in FY2021, compared to a net loss of EUR41.4 million in FY2020. The company reported revenues of EUR14.9 million for the third quarter ended September 2022, compared to a revenue of EUR7.3 million the previous quarter.

For a complete picture of AFM-13’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.